Dear members of the ESC Working Group on Cardiovascular Pharmacotherapy.
This bimonthly report summarizes developments of our WG during the last 4 months.
We experienced a marvellous growth of the WG, soon reaching the 800 member threshold. Since September 2018 we could approve 148 new members, a very steep rise.
Our educational programs, too, are in active development. The new course, ”Pharmacotherapy in Old People (POP)” was successfully started in October in London. Prof. Juan Carlos Kaski could gather a splendid faculty as well as around 50 participants. In December, Prof. Gianluigi Savarese chaired a well-attended and high-quality course “All About clinical trials” (AACT) in Stockholm. These two courses are now a stable entity within our WG program.
The logical consequence is that we created a new strategy for our annual EuroCVP congress. We will have 2 days with one day each for a POP and AACT program in Vienna in May 28-29. Please register now to this interesting programme!
We are also proud of the favourable development of our Journal with an impact factor of >6.7. This is very well respected in the ESC and worldwide, with a huge number of submissions, as we hear from the Editor-in-chief, Prof. Stefan Agewall.
Moreover, our ESC Handbook on Cardiovascular Pharmacotherapy is very well received, sold well, and already under update by the Editors Prof. Keld Kjeldsen and Juan Carlos Kaski.
With all these developments we face a bright future and our nucleus considers an upgrade of our WG to an ESC Association.
Saying all that, I wish to see soon you all in Vienna in May, please register now.
Heinz Drexel, MD, Professor
Chairperson of the ESC Working Group on Cardiovascular Pharmacotherapy
Our mission: To reduce the burden of cardiovascular disease.